IP Library › Granted Patent US 7,718,674
Granted Patent B2
US 7,718,674 · App. 11/236,263 · Granted May 18, 2010

Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine

Assignee: Bridge Pharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,674
App. No.
11/236,263
Granted
May 18, 2010
Kind
B2
Abstract

The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.

Claims (17)

1. A method of relieving neuropathic pain in a patient in need thereof, comprising administering to a discrete site in a patient in need thereof a neuropathic pain-relieving effective amount of the compound S-2-{2-[N-(2-indanyl)-N-phenylamino]ethyl}piperidine:

wherein administration of the compound to the discrete site provides a duration of action that is longer than that of the corresponding racemate and the corresponding R-isomer.

2. The method of claim 1 , wherein said pain is selected from the group consisting of neuropathic pain caused by AIDS/HIV, Herpes Zoster, syphilis, diabetes, and autoimmune diseases.

3. The method of claim 1 , wherein said site is an area with neuropathic pain.

4. The method of claim 1 , wherein administration of the compound provides relief of pain for about 5 minutes to about 48 hours.

5. The method of claim 1 , wherein administration of the compound provides relief of pain for about 24 hours to about 26 weeks.

6. The method of claim 1 , wherein the compound is a more than 95% optically pure S-isomer.

7. The method of claim 1 , wherein the compound is a more than 97% optically pure S-isomer.

8. The method of claim 1 , wherein the compound is a more than 99% optically pure S-isomer.

9. The method of claim 1 , wherein the compound attenuates or relieves neuropathic pain selected from the group consisting of pain from nerve injury, pain from neuralgia, pain from myalgias, pain associated with painful trigger points, pain from tumors in soft tissues, pain associated with neurotransmitter-dysregulation syndromes and neuropathic pain associated with orthopedic disorders selected from the group consisting of neuropathic conditions of the foot, knee, hip, spine, shoulders, elbow, hand, head and neck.

10. The method of claim 1 , wherein said site is a surgical site.

11. The method of claim 1 , wherein said neuropathic pain is associated with a condition selected from the group consisting of tendonitis, bursitis, osteoarthritis, and rheumatoid arthritis.

12. The method of claim 1 , wherein said neuropathic pain is associated with an orthopedic disorder of the foot selected from the group consisting of heel spurs, corns, bunions, Morton's neuroma, hammertoes, ankle sprain, fractures of the ankle or metatarsals or sesamoid bone or toes, plantar fascitis and injuries to the achilles tendon.

13. The method of claim 1 , wherein said neuropathic pain is associated with an orthopedic disorder of the hand selected from the group consisting of arthritis, carpal tunnel syndrome, and ganglion cysts.

14. The method of claim 1 , wherein said neuropathic pain is associated with a disorder selected from the group consisting of lateral epicondylitis, medial epicondylitis, rotator cuff tendonitis, DeQuervian's tenosynovitis, and trigger finger/trigger thumb.

15. The method of claim 1 , wherein said neuropathic pain is associated with a disorder selected from the group consisting of Paget's disease, scoliosis, contusions, sprains, strains, lower back pain, and heel spur.

16. The method of claim 1 , wherein said neuropathic pain is associated with a bone fracture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2010
From: ABERG, A.K. GUNNAR; CHEN, JAN L.
To: BRIDGE PHARMA, INC.
Reel/Frame 024022/0183 →
Continuity (2)
Provisional Application 6061338600 · Sep 27, 2004
Related Publication 20060079559A1 · Apr 13, 2006